THE PHARMACOLOGICAL ACTIVITY OF KETOROLAC TROMETHAMINE

被引:0
|
作者
ROOKS, WH
机构
来源
PHARMACOTHERAPY | 1990年 / 10卷 / 06期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ketorolac tromethamine is a highly potent member of a class of compounds having both analgesic and antiinflammatory activity. In animal pain models using underlying inflammation, ketorolac markedly inhibited the pain response and increased the pain threshold; it did not exhibit any narcotic or central nervous system depressant effects. It was also active in rat models of acute and chronic inflammation and pyresis. These activities are mediated primarily by potent prostagladin cyclooxygenase inhibitory activity. Mild central nervous system and cardiovascular effects occurred only at doses far greater than those required for analgesic and antiinflammatory activity. Solutions of ketorolac tromethamine are not irritating. When given intramuscularly to rabbits (0.31-5% solutions), no drug-related irritation or changes in serum creatine phosphokinase were seen. The agent was not irritating when applied to the skin or eyes (< 0.5% solutions) of animals.
引用
收藏
页码:S30 / S32
页数:3
相关论文
共 50 条
  • [21] Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis
    Schechter, Barry A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (04) : 507 - 511
  • [22] Preparation and evaluation of sublingual film of ketorolac tromethamine
    Bin Siddiqui, Md Husain
    Islam, Md Sazzadul
    Razu, Md Rashaduzzaman
    Zaman, Atkeya Nabila
    Jadi, Badsha
    Saha, Tanoy
    Pathan, Md Saiful Islam
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2022, 48 (09) : 438 - 445
  • [23] An update on the use of ophthalmic ketorolac tromethamine 0.4%
    Perry, HD
    Donnenfeld, ED
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (01) : 99 - 107
  • [24] Ketorolac tromethamine liposomes: Encapsulation and release studies
    Ruozi, B
    Tosi, G
    Forni, F
    Vandelli, MA
    JOURNAL OF LIPOSOME RESEARCH, 2005, 15 (3-4) : 175 - 185
  • [25] KETOROLAC TROMETHAMINE (KT) ABSORPTION AND PHARMACOKINETICS IN HUMANS
    MROSZCZAK, EJ
    LING, T
    YEE, J
    MASSEY, I
    SEVELIUS, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 215 - 215
  • [26] EFFECTS OF KETOROLAC TROMETHAMINE ON RENAL TUBULAR CELLS
    GOGUS, N
    ERK, G
    TOGAL, T
    KANBAK, O
    BRITISH JOURNAL OF ANAESTHESIA, 1995, 74 : 57 - 57
  • [27] Biodegradable microspheres of ketorolac tromethamine for parenteral administration
    Bhaskaran, S
    Suresh, S
    JOURNAL OF MICROENCAPSULATION, 2004, 21 (07) : 743 - 750
  • [28] Formulation of sustained - release ketorolac tromethamine pellets
    Etman, Mohamed
    Nada, Hala
    Nada, Aly
    Ismail, Fatma
    Moustafa, Mamdouh
    Khalil, Said
    Pharmaceutical Technology, 2008, 32 (12): : 58 - 61
  • [29] ANAPHYLACTOID REACTION FOLLOWING KETOROLAC TROMETHAMINE ADMINISTRATION
    GOETZ, CM
    STERCHELE, JA
    HARCHELROAD, FP
    ANNALS OF PHARMACOTHERAPY, 1992, 26 (10) : 1237 - 1238
  • [30] INCOMPATIBILITY OF KETOROLAC TROMETHAMINE WITH SELECTED POSTOPERATIVE DRUGS
    KNAPP, AJ
    MAURO, VF
    ALEXANDER, KS
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (12): : 2960 - 2962